SLN Stock Overview
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£5.35|
|52 Week High||UK£6.80|
|52 Week Low||UK£4.11|
|1 Month Change||5.94%|
|3 Month Change||-7.60%|
|1 Year Change||29.23%|
|3 Year Change||474.65%|
|5 Year Change||393.09%|
|Change since IPO||-78.81%|
Recent News & Updates
These Analysts Think Silence Therapeutics plc's (LON:SLN) Earnings Are Under Threat
Today is shaping up negative for Silence Therapeutics plc ( LON:SLN ) shareholders, with the analysts delivering a...
|SLN||GB Biotechs||GB Market|
Return vs Industry: SLN exceeded the UK Biotechs industry which returned 24.6% over the past year.
Return vs Market: SLN exceeded the UK Market which returned 11.6% over the past year.
|SLN Average Weekly Movement||5.9%|
|Biotechs Industry Average Movement||5.9%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.7%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: SLN is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SLN's weekly volatility (6%) has been stable over the past year.
About the Company
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body’s natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.
Silence Therapeutics Fundamentals Summary
|SLN fundamental statistics|
Is SLN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SLN income statement (TTM)|
|Cost of Revenue||UK£6.85m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.47|
|Net Profit Margin||-373.84%|
How did SLN perform over the long term?See historical performance and comparison
Is Silence Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: SLN (£5.35) is trading above our estimate of fair value (£0.07)
Significantly Below Fair Value: SLN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SLN is unprofitable, so we can't compare its PE Ratio to the UK Biotechs industry average.
PE vs Market: SLN is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SLN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SLN is overvalued based on its PB Ratio (29.4x) compared to the GB Biotechs industry average (6.3x).
How is Silence Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLN's revenue (10% per year) is forecast to grow faster than the UK market (4.9% per year).
High Growth Revenue: SLN's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SLN is forecast to be unprofitable in 3 years.
How has Silence Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SLN is currently unprofitable.
Growing Profit Margin: SLN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SLN is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.
Accelerating Growth: Unable to compare SLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).
Return on Equity
High ROE: SLN has a negative Return on Equity (-259.27%), as it is currently unprofitable.
How is Silence Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SLN's short term assets (£83.1M) exceed its short term liabilities (£18.4M).
Long Term Liabilities: SLN's short term assets (£83.1M) exceed its long term liabilities (£58.0M).
Debt to Equity History and Analysis
Debt Level: SLN is debt free.
Reducing Debt: SLN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SLN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SLN is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 21.2% per year.
What is Silence Therapeutics's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SLN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SLN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SLN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Rothera (58 yo)
Mr. Mark Andrew Rothera is President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since September 14, 2020. Mr. Rothera has experience in the biopharmaceutical industry, with...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD693.39K) is below average for companies of similar size in the UK market ($USD1.03M).
Compensation vs Earnings: Insufficient data to compare Mark's compensation with company performance.
Experienced Management: SLN's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Experienced Board: SLN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.2%.
Silence Therapeutics plc's employee growth, exchange listings and data sources
- Name: Silence Therapeutics plc
- Ticker: SLN
- Exchange: AIM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£484.837m
- Shares outstanding: 89.78m
- Website: https://www.silence-therapeutics.com
Number of Employees
- Silence Therapeutics plc
- 72 Hammersmith Road
- Greater London
- W14 8TH
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/29 22:51|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.